SUBSCRIBE
SUBSCRIBE

Fate Therapeutics

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
$60 Million Juno Therapeutics Deal Pushes Fate Therapeutics Up 80% in Premarket Trading
May 6, 2015
 · 
7 min read
Load More
AWARDS
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Fate Therapeutics to Present at Upcoming December Investor Conferences
November 26, 2024
 · 
1 min read
Press Releases
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 19, 2024
 · 
11 min read
Press Releases
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
November 18, 2024
 · 
10 min read
Press Releases
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
 · 
15 min read
Press Releases
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
November 11, 2024
 · 
8 min read
Press Releases
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 11, 2024
 · 
10 min read
Press Releases
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 4, 2024
 · 
1 min read
Press Releases
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2024
October 3, 2024
 · 
1 min read
Business
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
 · 
1 min read
Business
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
 · 
15 min read
Load More